Single Chain Antibody Patents (Class 424/135.1)
-
Publication number: 20140341904Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Patent number: 8889132Abstract: The invention relates to reagents and methods for detecting, diagnosing and screening for conditions associated with hydroxylated hypoxia inducible factor 1-? (HIF-1?). The invention also relates to novel monoclonal antibodies specific for hydroxylated HIF-1?, or binding fragments thereof, and related nucleic acids, vectors, cells and compositions, as well as methods of using the antibodies in methods of the invention.Type: GrantFiled: June 30, 2011Date of Patent: November 18, 2014Assignee: Mount Sinai HospitalInventors: Isabella Caniggia, Martin Post
-
Publication number: 20140335088Abstract: Methods of treating or delaying onset of a neurodegenerative disorder with ?-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble ?-synuclein oligomer and capable of binding a stabilized soluble ?-synuclein oligomer, the stabilized soluble ?-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the ?-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble ?-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with ?-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites or is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA).Type: ApplicationFiled: July 21, 2014Publication date: November 13, 2014Inventors: Lars Lannfelt, Joakim Bergström, Martin Ingelsson, Pär Gellerfors
-
Patent number: 8883152Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof. There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama. These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.Type: GrantFiled: March 18, 2013Date of Patent: November 11, 2014Assignee: University of GuelphInventors: J. Christopher Hall, Gabrielle Richard, Michael D. McLean
-
Patent number: 8883735Abstract: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.Type: GrantFiled: November 2, 2012Date of Patent: November 11, 2014Assignee: Novartis AGInventors: David Jenkins, Ming Lei, Andreas Loew, Li Zhou
-
Publication number: 20140328750Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Z. Chen
-
Publication number: 20140328846Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.Type: ApplicationFiled: June 11, 2014Publication date: November 6, 2014Inventor: Rekha Bansal
-
Publication number: 20140328845Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.Type: ApplicationFiled: April 1, 2014Publication date: November 6, 2014Applicant: ACCELERON PHARMA INC.Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
-
Patent number: 8877191Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.Type: GrantFiled: October 11, 2011Date of Patent: November 4, 2014Assignee: KaloBios Pharmaceuticals, Inc.Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
-
Patent number: 8877189Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: June 6, 2013Date of Patent: November 4, 2014Assignee: MedImmune LimitedInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Patent number: 8877199Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.Type: GrantFiled: May 12, 2010Date of Patent: November 4, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
-
Patent number: 8877186Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: GrantFiled: June 3, 2008Date of Patent: November 4, 2014Assignee: Domantis LimitedInventors: Michael Steward, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever, Laurent Jespers, Thil Dinuk Batuwangala
-
Publication number: 20140322220Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
-
Publication number: 20140322219Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 1, 2014Publication date: October 30, 2014Applicants: Vanderbilt University, Oregon Health & Science UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20140322218Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: January 27, 2014Publication date: October 30, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Shawn Jeffries, Chadwick T. King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
-
Publication number: 20140322217Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.Type: ApplicationFiled: January 14, 2014Publication date: October 30, 2014Applicant: Xencor, Inc.Inventors: Gregory MOORE, Matthew Bernett, Rumana Rashid, John Desjarlais
-
Patent number: 8865169Abstract: The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacterial proteins, viral proteins, cancer cells, and proteins or toxins produced therefrom. In particular, the present invention includes methods and systems for binding agents that are specific to neurotoxins that cause botulism.Type: GrantFiled: February 18, 2008Date of Patent: October 21, 2014Assignee: Tufts UniversityInventors: Charles B. Shoemaker, Jorge A. Sepulveda Toepfer, Jean Mukherjee
-
Patent number: 8865170Abstract: The present invention is novel anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibodies useful for treating tissue fibrosis or cancer, and pharmaceutical compositions containing the anti-human-CCR7 antibodies. The invention includes an anti-human-CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77. The invention also includes an anti-human-CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: GrantFiled: September 27, 2011Date of Patent: October 21, 2014Assignees: Sekisui Chemical Co., Ltd., NE Health Laboratory Co., Ltd.Inventors: Naoki Nishiguchi, Akiyoshi Hirayama, Masahiro Furutani, Tatsuo Shimizu, Kiyoshi Takayama, Tomoko Shimizu, Kazuya Suzuki
-
Publication number: 20140308283Abstract: This invention relates to a pharmaceutical composition for treatment and/or prevention of pancreatic cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 to 12 or more consecutive amino acid residues.Type: ApplicationFiled: August 3, 2012Publication date: October 16, 2014Applicant: TORAY INDUSTRIES, INC.Inventors: Yoshitaka Minamida, Fumiyoshi Okano, Takanori Saito
-
Publication number: 20140308284Abstract: Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.Type: ApplicationFiled: April 1, 2014Publication date: October 16, 2014Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: BO GYOU KIM, JI MIN LEE, KYUNG AH KIM, YUN JU JEONG
-
Patent number: 8859740Abstract: There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments and derivatives of such antibodies, and AIP2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having AIP2 related disorders or conditions. There is also disclosed a method to treat S. aureus infections by administering an anti-AIP2 antibody described herein.Type: GrantFiled: October 24, 2013Date of Patent: October 14, 2014Assignee: Sorrento Therapeutics Inc.Inventors: Gunnar F. Kaufmann, Heyue Zhou, Guodi Lu
-
Publication number: 20140302029Abstract: There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for preventing and/or treating cancer using the same, and an anti-EGFR scFv fragment.Type: ApplicationFiled: March 31, 2014Publication date: October 9, 2014Inventors: MI YOUNG CHO, SEUNG HYUN LEE, KWANG HO CHEONG, POWEI LIN, JAE WOONG HWANG, CHRISTINA YI, YOUNG JUN KOH
-
Publication number: 20140302033Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.Type: ApplicationFiled: November 9, 2012Publication date: October 9, 2014Applicant: UCB PHARMA S.A.Inventors: Ralph Adams, Pavalli Bhatta, Sam Phillip Heywood, David Paul Humphreys
-
Publication number: 20140302032Abstract: A method of treating a tumor or enhancing survival of a subject having a tumor. The method includes (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has all complementarity determining regions of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the subject an effective amount of at least one chemotherapeutic agent selected from the group consisting of: 5-fluorouracil, cytarabine, oxaliplatin, paclitaxel and combinations thereof. The humanized antibody is administered between 1 and 30 days after commencing chemotherapy or substantially simultaneously or concurrently or according to an overlapping schedule with the at least one chemotherapeutic agent to thereby treat the tumor or enhance the survival of the subject having the tumor.Type: ApplicationFiled: April 29, 2014Publication date: October 9, 2014Applicant: CURETECH LTD.Inventors: Rinat ROTEM-YEHUDAR, Galina RODIONOV
-
Publication number: 20140302144Abstract: The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts. The formulation can provide sustained release of antibody and antibody fragments, in particular, IgG. Antibody diffusivities can be decreased with increasing hydrogel nanofiber density, providing a means to control the release kinetics.Type: ApplicationFiled: March 14, 2014Publication date: October 9, 2014Applicant: Massachusetts Institute of TechnologyInventors: Sotirios Koutsopoulos, Shuguang Zhang
-
Publication number: 20140302030Abstract: Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.Type: ApplicationFiled: April 1, 2014Publication date: October 9, 2014Inventors: BO GYOU KIM, JI MIN LEE, KYUNG AH KIM, YUN JU JEONG
-
Publication number: 20140302031Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.Type: ApplicationFiled: April 14, 2014Publication date: October 9, 2014Applicant: The Brigham and Women's Hospital, Inc.Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
-
Publication number: 20140302129Abstract: Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventors: Susan J. Drapeau, Guobao Wei
-
Patent number: 8852588Abstract: Treatment of an allergic airway disorder (e.g., asthma or bronchial airway obstruction) using anti-IL-20R1 antibodies such as mAb51D, mAb7GW, or functional variants thereof.Type: GrantFiled: August 7, 2012Date of Patent: October 7, 2014Assignee: National Cheng Kung UniversityInventor: Ming-Shi Chang
-
Patent number: 8852589Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.Type: GrantFiled: October 17, 2013Date of Patent: October 7, 2014Assignee: Medical Research CouncilInventors: Andrew Neil James McKenzie, Daniel Neill
-
Publication number: 20140294828Abstract: The invention provides methods for the production of single-chain Alphabody polypeptides having detectable binding affinity for, or detectable in vitro activity on, a viral protein of interest, which comprising the step of producing a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein said variegated amino acid residue positions are located at specific positions in one or more of the alpha-helices of the Alphabody or the linker fragment connecting two consecutive alpha-helices of the Alphabody polypeptides. The invention further provides Alphabodies obtainable by the methods of the invention and uses thereof.Type: ApplicationFiled: January 6, 2011Publication date: October 2, 2014Applicant: COMPLIX SAInventors: Johan Desmet, Ignace Lasters, Geert Meersseman, Sabrina Deroo
-
Publication number: 20140294829Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including pain, asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.Type: ApplicationFiled: March 24, 2014Publication date: October 2, 2014Applicant: GENENTECH, INC.Inventor: David L. Shelton
-
Publication number: 20140294830Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.Type: ApplicationFiled: March 27, 2014Publication date: October 2, 2014Applicants: SAMSUNG LIFE WELFARE FOUNDATION, SAMSUNG ELECTRONICS CO., LTD.Inventors: Saet Byoul LEE, Jae Hyun Choi, Kyung Ah Kim, Ji Min Lee, Yun Ju Jeong
-
Publication number: 20140294824Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: March 21, 2014Publication date: October 2, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
-
Publication number: 20140294831Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: May 19, 2014Publication date: October 2, 2014Applicant: iPierian, Inc.Inventors: Irene GRISWOLD-PRENNER, Nancy E. STAGLIANO, Vu DANG
-
Publication number: 20140294827Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.Type: ApplicationFiled: March 30, 2013Publication date: October 2, 2014Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
-
Publication number: 20140286949Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.Type: ApplicationFiled: October 25, 2013Publication date: September 25, 2014Applicant: Dana-Farber Cancer InstituteInventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen
-
Publication number: 20140286950Abstract: This invention relates to compositions comprising anti-CD83 agonist antibodies and methods of treating autoimmune disorders (such as inflammatory bowel disease) with anti-CD83 agonist antibodies, as well as articles of manufacture comprising anti-CD83 agonist antibodies.Type: ApplicationFiled: June 29, 2012Publication date: September 25, 2014Applicant: Genentech, Inc.Inventors: Lauri Diehl, Jennifer Bates, Tao Sai
-
Publication number: 20140286861Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: ApplicationFiled: April 23, 2014Publication date: September 25, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
-
Patent number: 8840885Abstract: The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are useful in studying and treating cancer.Type: GrantFiled: February 16, 2011Date of Patent: September 23, 2014Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, John McWhirter
-
Patent number: 8840888Abstract: Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.Type: GrantFiled: October 27, 2010Date of Patent: September 23, 2014Assignee: Micromet AGInventors: Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Baeuerle
-
Publication number: 20140271645Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: ApplicationFiled: April 18, 2014Publication date: September 18, 2014Applicant: ZYMOGENETICS, INC.Inventors: Penny THOMPSON, Hal BLUMBERG, Yasmin A. CHANDRASEKHER, Julia E. NOVAK
-
Publication number: 20140271644Abstract: In an attempt to improve primary disease responsiveness and/or to overcome resistant disease, the present disclosure provides a method for treating or inhibiting the proliferation of a WT-1-dependent cancer comprising providing to a subject in need thereof a therapeutically effective amount of a tyrosine kinase inhibitor along with an anti-WT-1/HLA antibody, that is, an antibody that specifically binds to a peptide of Wilms' tumor protein (WT-1) presented on the surface of the cancer cells in an HLA-restricted fashion.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Memorial Sloan-Kettering Cancer CenterInventors: David Scheinberg, Leonid Dubrovsky
-
Publication number: 20140271646Abstract: Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.Type: ApplicationFiled: October 16, 2012Publication date: September 18, 2014Inventors: Dimiter S. Dimitrov, Weizao Chen, Yang Feng
-
Publication number: 20140271464Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Alderbio Holdings LLCInventors: Leon F. GARCIA-MARTINEZ, Andrew L. Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
-
Patent number: 8834879Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.Type: GrantFiled: April 3, 2013Date of Patent: September 16, 2014Assignee: ZymoGenetics, Inc.Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
-
Publication number: 20140255404Abstract: The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension.Type: ApplicationFiled: October 23, 2012Publication date: September 11, 2014Applicant: PH TherapeuticsInventor: Allan Lawrie
-
Publication number: 20140255304Abstract: Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicants: BIOGEN IDEC INTERNALTIONAL NEUROSCIENCE GMBH, UNIVERSITY OF ZURICHInventors: Nitsch Roger, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Patent number: 8828670Abstract: The invention relates to a method for producing monomeric or dimeric proteins or peptides containing internal or external disulfide bonds, comprising the following steps: a) a cell-free lysate, obtainable from eukaryotic cells, is provided, which contains functional microsomal vesicles, b) a nucleic acid coding the protein or peptide and additionally containing a signal sequence is added to the lysate, c) the lysate with the nucleic acid is held for a given time at a temperature in the range from 20 to 35° C., proteins or peptides formed with the nucleic acid being translocated into the microsomal vesicles, d) the microsomal vesicles are then dissolved, and the proteins or peptides obtained thereby are optionally separated from the lysate.Type: GrantFiled: July 10, 2012Date of Patent: September 9, 2014Assignee: RiNA Netzwerk RNA Technologien GmbHInventors: Helmut Merk, Wolfgang Stiege, Christine Gless, Michael Gerrits
-
Patent number: 8828382Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.Type: GrantFiled: September 26, 2008Date of Patent: September 9, 2014Assignees: U3 Pharma GmbH, Amgen Inc.Inventors: Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord